23
Jun
Glenmark Pharmaceuticals Ltd. (Glenmark) an integrated, research‐led, global pharmaceutical company, today announced a price reduction of Trastuzumab for HER2-positive breast cancer, being marketed in India under the brand name ‘ Trumab’. A 440 mg vial of Trumab will be priced at INR 15,749, which makes it the most affordable option available currently in the country. Trastuzumab is a monoclonal antibody used to treat HER2-positive breast cancer in India, costing INR 40,000-54,000 per 440mg vial. Out of pocket expenses account for 52% of health care financing in India. Breast cancer is the most commonly diagnosed cancer in India, with an estimated…
